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Pararenal aortic aneurysm repair using
fenestrated endografts
Matteus A. M. Linsen, MD,a Vincent Jongkind, MD,a Denise Nio, MD,b Arjan W. J. Hoksbergen, MD,a
and Willem Wisselink, MD,a Amsterdam and Hoofddorp, The Netherlands
Objective: We performed a systematic review of the current literature to analyze the immediate and follow-up results of
fenestrated endovascular aortic aneurysm repair (F-EVAR) in patients with pararenal abdominal aortic aneurysms
(AAAs).
Methods: The Medline, Embase, and Cochrane databases were searched to identify all studies reporting F-EVAR of
pararenal AAAs published between January 2000 and May 2011. Two independent observers selected studies for
inclusion, assessed the quality of the included studies, and performed the data extraction. Studies were selected based on
specific predefined criteria. Outcomes were technical success (successfully completed procedure with endograft patency,
preservation of target vessels, and no evidence of type I or III endoleak at postprocedural imaging), 30-day mortality,
all-cause mortality, branch vessel patency, renal impairment, and secondary interventions. Between-study heterogeneity
was calculated using I2 statistics. Pooled estimates were calculated using a fixed-effects (I2<25%) or a random-effects (I2
>25% to <50%) model.
Results:Nine studies were included reporting 629 patients who underwent F-EVAR for a pararenal AAA, of which 1622
target vessels were incorporated in an endograft design. Between-study heterogeneity was <41% for all outcomes. The
pooled estimate (95% confidence interval [CI] was 90.4% (87.7%-92.5%) for technical success, 2.1% (1.2%-3.7%) for
30-day mortality, and 16% (12.5%-20.4%) for all-cause mortality. Follow-up was 15 to 25 months. The pooled estimate
(95% CI) during follow-up was 93.2% (90.4%-95.3%) for branch vessel patency, 22.2% (16%-30.1%) for renal impair-
ment, and 17.8% (13.5%-22.6%) for secondary interventions.
Conclusions: Promising immediate and midterm results (up to 2 years) support F-EVAR as a feasible, safe, and effective
treatment in a relatively high-risk cohort of patients with pararenal AAAs. (J Vasc Surg 2012;56:238-46.)
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oAbdominal aortic aneurysms (AAAs) that closely ap-
proach or involve the renal arteries can be classified as
juxtarenal or thoracoabdominal (Crawford) type IV aneu-
rysms.1 Juxtarenal aneurysms extend proximally to the
origin of the renal artery without involving the artery itself,
whereas thoracoabdominal type IV include most or all of
the entire abdominal aorta, including the renal arteries.1
Compared with infrarenal AAAs, open surgical repair of
these more complex aneurysms is characterized by more
extensive mobilization of viscera to achieve adequate expo-
sure of the abdominal aorta and may involve prolonged
suprarenal aortic clamping and the need for revasculariza-
tion of visceral vessels. Owing to inadequate proximal
neck length, standard endovascular aortic aneurysm repair
(EVAR) cannot provide a minimally invasive alternative for
these complex aneurysms.
To overcome these problems, fenestrated EVAR (F-
EVAR) has been developed. Fenestrated endografts are
designed to extend the range of EVAR by moving the
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238roximal sealing zone up to and above the level of the renal
rteries, thereby providing endovascular repair of juxtarenal
nd Crawford type IV aneurysms. Following on the efforts
f a few vascular specialists from Australia during the last
ecade, fenestrated endografts progressed from bench-top
o broad clinical application and are now used commercially
n Europe, Australia, and other locations.2-4
The present study performed a systematic review of the
urrent literature to analyze the immediate and follow-up
esults of F-EVAR in patients with juxtarenal or Crawford
ype IV aortic aneurysms.
ETHODS
A systematic review was performed according to the
uidelines of the Meta-analysis Of Observational Studies in
pidemiology group (MOOSE) and the Dutch Cochrane
entre.5,6 Two investigators (M.L. and V.J.) indepen-
ently conducted a literature search, quality assessment,
nd data extraction.
Search strategy. A computer-assisted search was per-
ormed in the medical databases Medline, Embase, and the
ochrane Database of Systematic Reviews, from January
000 to May 2011, using a combination of the following
ree-text words: aortic aneurysm, AAA, complex aneurysm,
uxtarenal, pararenal, suprarenal, endovascular repair,
VAR, graft, endograft, stent-graft, fenestrated, and F-
VAR. With the assistance of a clinical librarian, an addi-
ional extensive search was performed using a combination
f Medical Subject Heading (MeSH) terms: vascular dis-
ases, aortic aneurysm; aortic aneurysm, abdominal; vascu-
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Volume 56, Number 1 Linsen et al 239lar surgical procedures, vascular prosthesis, vascular graft-
ing, endovascular procedures, endovascular technique, blood
vessel prosthesis implantation, and stents.
Electronic links to related articles and reference lists of
selected articles were hand-searched to retrieve more stud-
ies. A hand-search for relevant journals and conference
proceedings was not performed, nor was a search for un-
published data or abstracts performed. Relevant studies
were selected for full-text review based on title and abstract.
Study selection. Any prospective or retrospective
study was considered. Studies were eligible if they (1)
evaluated totally endovascular repair of juxtarenal or
Crawford type IV aortic aneurysms using fenestrated
endografts, (2) included at least 10 cases, (3) reported
aneurysm morphology, (4) clearly stated the number of
target vessels and their status (patent, stenosis, occlu-
sion), (5) and observed a mean or median follow-up
period of at least 6 months. Studies had to describe an
original patient series. In case series reported on more
than one occasion, the report containing the most com-
plete outcomes information was included for analysis.
The selection process excluded articles in languages
other than English, Dutch, or German.
Methodologic quality assessment. Each article in-
cluded was assessed according to the critical review check-
list of the Dutch Cochrane Centre5 (Table I). This list
evaluates the quality of the study by using the following key
statements that in the form of questions can be answered
with yes (), no (), and uncertain (). The main points
of this checklist are:
1. Clear definition of study population?
2. Can selection bias be excluded sufficiently?
3. Clear description of method of intervention?
4. Clear definition of outcomes and outcome assessment?
5. Independent assessment of outcome parameters?
6. Sufficient duration of follow-up?
7. No selective loss to follow-up?
8. Important confounders and prognostic factors identified?
Each study was further evaluated using a list of detailed
study characteristics as proposed by the MOOSE group.6
Studies were scored on eight items. Each item was graded
on a scale of 0 to 2, depending on the information available,
Table I. Quality assessment list of included studies
First author (year)
Clear definition of
study population?
Can selection
excluded suffi
Semmens42 (2006) – –
O’Neill43 (2006)  –
Scurr44 (2007)  –
Ziegler45 (2007)  –
Kristmundson46 (2008)  
Greenberg47 (2009)  
Verhoeven48 (2010)  –
Amiot49 (2010)  –
Tambyraja50 (2011)  –so that the perfect study would have a maximum score of c6. Studies with a score of 8 were considered to be of
oor methodologic quality and were not included in our
eview. Quality score was determined by whether the study
eported a consecutive series, a prospective series, reported
xcluded patients, indication for intervention, and a de-
ailed description of target vessels, complications, and mor-
ality.
Data extraction. Data were extracted using a stan-
ardized form. If recorded, the following information was
xtracted: publication year, country of origin, enrollment
pan, number of patients and their demographics (mean
ge, sex), anatomy (type of aneurysm, proximal neck
ength), procedure (type of endograft, procedure time,
ype of anesthesia used, contrast volume used, fluoroscopy
ime, number of target vessels, complications, results of
ostprocedural imaging), and follow-up results (mean/
edian follow-up, 30-day mortality, all-cause mortality,
neurysm rupture, hospital stay, renal impairment, new-
nset dialysis, branch vessel patency, reinterventions, major
dverse events). Any discrepancies in judgment considering
earch strategy, selection of articles, quality assessment, or
ata extraction were resolved by discussion between all
uthors. Final decisions were made after consensus was
eached.
Statistical analysis. Between-study statistical hetero-
eneity was assessed using I2 statistics. In case of low
eterogeneity (I2 25%) a fixed-effects model was used
Mantel-Haenszel method), and in case of moderate het-
rogeneity (I2 50%) a random-effects model was used
DerSimonian-Laird model). Meta-analyses were per-
ormed for technical success, 30-day mortality, all-cause
ortality, branch vessel patency, renal impairment, and
econdary interventions. Pooled estimates are presented
ith 95% confidence intervals (CI). Analyses were done
sing Meta-Analyst, 3.0 beta software (Tufts Medical Cen-
er, Boston, Mass).7
Definitions. The term pararenal aortic aneurysm was
sed to define juxtarenal and Crawford type IV aortic
neurysms. Technical success was defined as successfully
ompleted F-EVAR procedure with endograft patency,
reservation of target vessels, and no evidence of type I or
II endoleak at postprocedural imaging. Renal impairment
as defined as a transient or permanent increase in serum
be
y?
Clear description of
method of intervention?
Clear definition of outcomes and
outcome assessment?
 
 
 
 
 
 
 
 
 bias
cientlreatinine 2 mg/dL or by a 30% increase compared with
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July 2012240 Linsen et albaseline levels. Renal impairment was also reported accord-
ing to the Society for Vascular Surgery reporting standards
as no dialysis, temporary dialysis, or permanent dialysis,
transplantation, or fatal outcome.8 Target vessel patency
was defined as target vessels without (re)stenosis or occlu-
sion that did not require a reintervention during follow-up.
The reintervention rate was defined as a repeat procedure
for complications that were aneurysm- or endograft-related
(eg, endoleak, target vessel preservation related) or a result
of the initial procedure (eg, wound infection).
RESULTS
The search identified 173 articles, of which 44 studies
were selected for full-text review based on title and abstract.
Thirty-five studies were excluded after full-text review.
Study flow and reasons for exclusion are presented in Fig 1.
We excluded two technical reports,9,10 three small case
series or reports,3,11,12 six review articles,13-18 four articles
that reported techniques other than fenestrated en-
dografts,19-22 and four studies that reported data of an
irrelevant cohort.23-26 One study was excluded because it
only reported early outcome and no follow-up was de-
Fig 1. Flow chart illustrates study selection.
Table I. Continued.
Independent assessment
of outcome parameters?
Sufficient duration
of follow-up?
No selective loss
follow-up?
–  
–  
–  
–  
–  
  
–  
–  
–  scribed.27 Several institutes were overrepresented in the belected studies. Only the largest, most complete series
ere used, leading to a reduction of 15 articles.2,28-41
Study quality. Nine studies were included in this anal-
sis.42-50 All studies were observational, two were of pro-
pective and seven of retrospective design. Quality assess-
ent of the studies (Table I) showed a suspected selection
ias of patients in most studies. The total quality score of
he description of the study characteristics is shown in the
ast column of Table I. Although operative and follow-up
ata were well documented, their quality was influenced on
hether data were retrospectively or prospectively acquired
nd if patients were consecutively included.
Preprocedural patient characteristics. The included
rticles represented 629 patients undergoing F-EVAR of
ararenal AAAs between 1997 and 2010. Age was reported
sing mean and median (range, 70.5-75.5 years), and 557
atients (88.6%) were men. Aneurysm size was reported by
ight studies, and bothmean andmedian were used (range,
5.1-68 mm). Only four studies reported mean or median
roximal neck length (range, 3.6-9.2 mm). Most patients
ad significant comorbidities, were deemed high risk for
pen repair, and were not eligible for conventional EVAR.
nly four studies reported the American Society of Anes-
hesiologists (ASA) score. Previous open surgical AAA re-
air had been performed in 31 patients (4.9%), and 12
1.9%) had undergone previous EVAR. Mean or median
uration of follow-up was 15 to 25 months. Patient and
tudy characteristics are summarized in Table II.
The included studies all used Zenith fenestrated en-
ografts (Cook Inc, Indianapolis, Ind). This device is a
odular system that contains a tubular proximal fenes-
rated component, a distal bifurcated component, and one
imb extension. Endografts are individually customized
ccording to the precise plans of the location of the visceral
rteries (target vessels) to be preserved. Most target vessels
re stented open using bare or covered balloon-expandable
tents. This ensures proper alignment of the fenestration
nd the orifice of the target vessel. A step-by-step technical
escription was published by Moore et al.51
Procedural data and early outcome. A total of 1622
arget vessels were incorporated in an endograft design, and
he renal artery was included 1144 times (Table III). Each
atient received between two and three fenestrations (Ta-
Important confounders and
prognostic factors identified?
Quality score of description
of study characteristics?
 10
 11
 12
 10
 13
 16
 10
 10
 13tole III). Details of whether fenestrations were stented open
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were poorly described. Only four studies provided the type
of anesthesia used, indicating general anesthesia was used in
61.6%, and local or regional was used in the rest.
Procedure time was reported using both mean and
median and was between 180 and 350 minutes. The mean
or median reported fluoroscopy time was 34.3 to 78 min-
utes, and 96.3 to 270 mL of contrast volume was used. All
studies provided data to determine technical success. The
pooled estimate for technical success was 90.4% (95% CI,
87.7%-92.5%; I2  20%; Fig 2). Two patients required
immediate open conversion. In one patient, an occlusion of
the native aortic bifurcation was identified after successful
endograft implantation, and an aortobifemoral bypass graft
was placed. The other patient required conversion during
endograft placement. Owing to twisting of the ipsilateral
limb, the top cap could not be retrieved and further at-
tempts resulted in crushing the already-placed renal stents.
In four patients, fenestrated endograft placement had to be
abandoned. In two patients, correct alignment of fenestra-
tion with target vessel ostia could not be achieved. The
third patient was found to have an incorrect endograft size,
and in the fourth patient, the imaging equipment failed
intraoperatively. Both patients were rescheduled for F-
Table II. Demographics and patient characteristics of incl
First author (year) Country
Enrollment
span
Pati
(No
Semmens42 (2006) Australia 1997-2004 5
O’Neill43 (2006) USA 2001-2005 11
Scurr44 (2007) UK 2003-2006 4
Ziegler45 (2007) Germany 1999-2006 6
Kristmundson46 (2008) Sweden 2002-2007 5
Greenberg47 (2009) USA 2005-2006 3
Verhoeven48 (2010) Netherlands 2001-2009 10
Amiot49 (2010) France 2004-2009 13
Tambyraja50 (2011) UK 2005-2010 2
NR, Not reported.
aResults are expressed as medians.
bReported during follow-up of 30 patients: 27 at 1 year and 23 at 2 years
Table III. Total of incorporated target vessels, their distri
incorporated in endograft design
Target vessels Ren
First author (year) (No.)
Semmens42 (2006) 116
O’Neill43 (2006) 302
Scurr44 (2007) 117
Ziegler45 (2007) 119
Kristmundson46 (2008) 134
Greenberg47 (2009) 77
Verhoeven48 (2010) 275
Amiot49 (2010) 403
Tambyraja50 (2011) 79
NR, Not reported; SMA, superior mesenteric artery.EVAR at a later time. oAt postprocedural imaging, the incidence of type I and
II endoleaks was 4.6%, and preservation of target vessels
as successful in 1603 vessels (99%). Causes for target
essel loss included planning errors, incorrect endograft
eployment, failed target vessel catheterization, and target
essel dissection.
No intraoperative deaths were reported. Ten patients
ied 30 days after the primary procedure. The pooled
stimate for 30-day mortality was 2.1% (95% CI, 1.2%-
.7%; I2  0%; Fig 3). Causes of death were myocardial
nfarction in three, mesenteric ischemia in two, pulmonary
omplications in two, and multiorgan failure in three (two
fter a major bleeding and one after conversion).
Follow-up results. Target vessel patency was reported
n all studies. The pooled estimate for target vessel patency
t the end of follow-up was 93.2% (95% CI, 90.4%-95.3%;
2 41%; Fig 4). The pooled estimate for renal impairment
t the end of follow-up, as reported by six studies, was
2.2% (95% CI, 16%-30.1%; I2  39%). Only 13 patients
2.1%) required dialysis, but whether dialysis was transient
r permanent was poorly described. No patient required
enal transplantation, and no fatal outcomes after renal
mpairment were described.
The pooled estimate for all-cause mortality at the end
studies
Age
years)
Sex M/F
(No.)
Aneurysm
size
(mm)
Proximal neck
length
(mm)
Follow-up
(months)
75.5 51/7 NR NR 18
75 98/21 65 8 19
73a 41/4 68a 6a 24a
70.5 54/6 55.1 NR 23
72a 46/8 60a NR 25a
75 24/6 61.4 9.2 27; 23b
72.6 87/13 60a 3.6 24a
73a 129/5 56a NR 15a
74a 27/2 68 NR 20a
n among visceral vessels and the ratio of fenestrations
eries SMA Celiac axis
Fenestration/
patient ratio
(No.) (No.) (No.)
24 1 2.0
76 1 2.5
35 2 2.6
22 9 2.0
37 3 2.5
20 0 2.5
78 5 2.8
NR NR 3.0
25 2 2.7uded
ents
.) (
8
9
5
0
4
0
0
4
9butio
al art
(No.)
91
225
80
88
94
57
192
265
52f follow-up was 16% (95% CI, 12.5%-20.4%; I2  29%).
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curred during follow-up at 30 days postoperatively. One
patient died after aneurysm rupture at 10 months, probably
caused by a type I endoleak. One patient died on day 45 as
a result of mesenteric ischemia. Two patients died of com-
plications subsequent to renal angioplasty in one and sur-
gery of the groin related to infection in the other. One
patient died of multiorgan failure related to massive athe-
roembolism, and one died in connection with an aortoduo-
denal fistula at 72 months. Nonfatal and nonrenal morbid-
ity was poorly described or not mentioned at all, hindering
an accurate analysis of the reported data.
All authors reported patients that required reinterven-
tions. At the end of follow-up, the pooled estimate for
reinterventions was 17.8% (95% CI, 13.5%-22.6%; I2 
34%). This included one secondary conversion to open
repair after aneurysm growth caused by a type I endoleak
and six patients requiring laparotomy for various reasons
(three for suspected mesenteric ischemia, two for acute
bleeding, and one for open repositioning of the endograft
and a bypass from the right iliac artery to the right renal
artery). Other secondary procedures were evacuation of a
retroperitoneal hematoma in two patients, endoleak repair
in 40 (16 type I, 14 type II, and 10 type III), target vessel
patency related in 36, wound and access-site related in 12,
and placement of an iliac limb extension in six.
DISCUSSION
The primary aim of F-EVAR is successful aneurysm
exclusion in a surviving patient who is protected from
Fig 2. Forest plot shows technical success rate in all stud
aneurysm repair procedure with endograft patency, pre
endoleak at postprocedural imaging. CI, Confidence intrupture with target vessel patency and is free of major hdverse events. The results of our systematic review indicate
hat F-EVAR of pararenal aneurysms can be performed
ith a low 30-daymortality rate of 2.1%. This is comparable
o the 1.7% rate reported after conventional EVAR and
ppears to be superior to the 2.9% rate after open pararenal
AA repair, as reported in a recent meta-analysis.52,53 This
s remarkable considering that most of the patients in our
nalysis had significant comorbidities and were deemed
unfit” or “high risk” for open repair. Moreover, a number
f patients underwent F-EVAR after previous open aortic
urgery or conventional EVAR. In comparison, the re-
orted 30-day mortality by the EVAR 2 trial (patients
onsidered high risk and unfit for open repair that under-
ent conventional EVAR) was more than three times higher
6.8%).54 Although remarkable, the difference is probably
aused by a more moderate inclusion of patients by studies
ncluded in this meta-analysis. This hypothesis is supported by
he relatively low all-cause mortality of 16% found in this
eta-analysis.
The technique of F-EVAR is more complex than that of
onventional EVAR. It requires appropriate patient selec-
ion, high-resolution preoperative imaging, accurate pro-
edural planning, proper device design, and excellent en-
ovascular and catheter skills. Failure to accomplish this
ay result in target vessel loss, endoleaks, or the need for
onversion to open repair. Technical success was achieved
n 90.4% of all cases. The immediate conversion rate was
ow (0.3%) and comparable to conventional EVAR
0.8%).52
Owing to the definition used, technical success was
fined as successfully completed fenestrated endovascular
ion of target vessels, and no evidence of type I or IIIies, de
servatighly dependent on whether intraoperative complications
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stage. Technical success was determined at the end of the
procedure, and therefore, the interventions that were done
within the first postoperative days were considered a failure
in technical success. This resulted in higher secondary
intervention and lower technical success rates. Further-
more, failure in technical success is not always a failure in
treatment success. For example, primary type I endoleaks
represent a failure to exclude an aneurysm and are a cause of
aneurysm growth with the risk of aneurysm rupture. How-
ever, small endoleaks found on postprocedural angiogra-
phy may resolve in time without consequences or the need
for reintervention.43-45 Moreover, target vessel loss with-
out clinical sequelae has been reported.44-46
The durability of F-EVAR has been questioned. There
is a concern with target vessel patency and renal impair-
ment.31 Loss of branch vessel patency can occur during the
initial procedure or over time due to endograft migration,
component separation, stent fracture, or in-stent stenosis.
Very few target vessels were lost during the initial proce-
dure, and branch vessel patency during follow-up was
93.2%. The combined transient and permanent renal im-
pairment rate in this analysis was 22.2%. This seems com-
parable to that reported for open pararenal aneurysm re-
Fig 3. Forest plot shows 30-day mortpair,53 but accurate comparison is difficult due to the wide pariety of definitions used. The incidence of new-onset
ialysis, however, was 2.1% in this review compared with
.3% reported after open pararenal repair.53 Renal dysfunc-
ion was obviously related to the loss of renal artery patency
ut also occurred in patients with confirmed patency. Early
enal impairment is likely associated with atheroembolic
vents that occur due to device and catheter manipulation.
he use of nephrotoxic contrast agents can also alter renal
unction, especially when preoperative renal function is
lready impaired.
EVAR is associated with higher rates of reintervention
han open repair.55 The reintervention rate of F-EVAR in
his analysis was 17.8%. Taking into account a shorter
ollow-up (up to 2 years), but also the more complex
ndograft design, this result seems comparable with the
0% reintervention rate after reported at the 4-year fol-
ow-up after conventional EVAR.55 Noteworthy is the
elatively high number of type III endoleaks. Compared
ith standard EVAR, F-EVAR requires an additional prox-
mal fenestrated component. The additional connection
etween this component and the bifurcated component
ay result in a higher type III endoleak rate. This compli-
ation can be easily eliminated by increasing the overlap-
or all studies. CI, Confidence interval.ing zone between the two main body components.45,47
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tion of F-EVAR, only a small number of dedicated centers
have accumulated significant experience with this tech-
nique, and information about outcomes, particularly in the
longer term, remains limited. The 629 patients in the
pooled data represent just a part of the total number of
patients treated with this technique worldwide. Other data
have not (yet) been published or have been published
combined with results for thoracoabdominal aneurysm re-
pair. The included studies well described aneurysm type
and patient characteristics; however, only four studies
stated proximal aortic neck length, and a wide variety of
definitions to describe the extent of aneurysmal disease
were used. It is therefore not clear if treatment of the same
aneurysm morphology was compared. The incorporation
of more target vessels in endograft design to treat more
complex aneurysms clearly results in an increased compli-
cation rate and higher risk for patency loss.
Furthermore, most of the patients were deemed at high
risk for open repair, but only four studies reported ASA
scores. How many patients were actually at high risk for
open surgery is unclear. Owing to these confounders, some
clinical heterogeneity was suspected between studies; nev-
ertheless, we decided to perform a pooled analysis for the
different outcomes. Between-study statistical heterogene-
ity subsequently was low or at least moderate, with an I2
value of 41% for all outcomes.
The included studies represent a relatively long period
for a new technique under development. This period in-
cludes the early years when fenestrated endografts were in
their infancy. We have to take into consideration that every
Fig 4. Forest plot shows branch vessel pnew procedure, especially one that is technically challeng- ong, is subject to a learning curve. Furthermore, improve-
ents in techniques and materials have been made over
ime. These factors will likely have negatively influenced the
arly outcomes. However, less demanding cases were se-
ected during the early years, and single scallops or fenes-
rations were incorporated in the endograft design. More
hallenging anatomies were targeted at a later stage, incor-
orating three fenestrations, one for each renal artery and
ne for the superior mesenteric artery and a scallop for the
eliac axis.
ONCLUSIONS
This review shows that the immediate and midterm
esults (up to 2 years) for F-EVAR are very promising.
ooled results support F-EVAR as a feasible, safe, and
ffective treatment in patients with pararenal AAAs and
ignificant comorbidities. F-EVAR can be performed with
ood technical success and with acceptable 30-day mortal-
ty and target vessel patency. However, postoperative dete-
ioration of renal function is a common complication,
echnical complications can occur intraoperatively and
ostoperatively, and as in conventional EVAR, a significant
mount of reintervention is necessary.
Obviously, the long-term durability remains to be in-
estigated, and due to missing randomized trials, compar-
son with open pararenal AAA repair is difficult. For now,
-EVAR, in the hands of an experienced surgeon, can be a
iable alternative to open pararenal AAA repair. It may be
he only option for patients with pararenal AAAs who are
onsidered high risk for open aneurysm repair and who
y for all studies. CI, Confidence interval.therwise would be denied treatment.
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